China approves use of Roche arthritis drug for some Covid-19 patients


  • China
  • Wednesday, 04 Mar 2020

BEIJING (Reuters): China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe condition, health authorities said on Wednesday (March 4), as the country seeks to build up treatment regimens to help the infected recover.

Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients who show serious lung damage and an elevated level of a protein called Interleukin 6, which could indicate inflammation or immunological diseases, the National Health Commission said in the latest version of its treatment guidelines published online.

Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

China , Roche , covid-19 , arthritis , drug

   

Next In Regional

Thailand drops joint patrols with Chinese police after public backlash
Cops on the hunt for cable thieves in Ayer Hitam
Najib wanted to answer questions on money laundering in court, says investigating officer
Hearing for Siti Bainun's appeal against conviction postponed to Jan 30 next year
Biker ambushed by a tiger near Gua Musang, lives to tell his tale
Historic day for human rights in Malaysia, says Azalina
Many workers in boycott-hit companies are locals, says Rayer
Two nabbed for launching fireworks at police in Lembah Subang
Federal Court commutes death, natural life jail sentences of 11 convicted for drug trafficking
RM15,000 max recruitment cost for new Indonesian domestic worker, says Human Resources Ministry

Others Also Read